Journal of Diabetes and Its Complications
Volume 24, Issue 2 , Pages 73-78 , March 2010

Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion

  • Tina K. Thethi, MD

      Affiliations

    • Tulane University Health Sciences, New Orleans, LA, USA
    • Corresponding Author InformationCorresponding author. Tulane University Health Sciences Center, 1430 Tulane Avenue, SL- 53, New Orleans, LA 70112, USA. Tel.: +1 504 988 5044; fax: +1 504 988 6271.
    • ,
  • Ajay Rao, MD

      Affiliations

    • Tulane University Health Sciences, New Orleans, LA, USA
    • ,
  • Haytham Kawji, MD

      Affiliations

    • Tulane University Health Sciences, New Orleans, LA, USA
    • ,
  • Tilak Mallik

      Affiliations

    • Diabetes-Endocrinology Center, Marrero, LA, USA
    • ,
  • C. Lillian Yau, PhD

      Affiliations

    • School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA
    • ,
  • Uwe Christians, MD, PhD

      Affiliations

    • Department of Anesthesiology, University of Colorado at Denver and Health Sciences Center, Denver, CO, USA
    • ,
  • Vivian Fonseca, MD

      Affiliations

    • Tulane University Health Sciences, New Orleans, LA, USA

Received 9 July 2008 ,Revised 16 February 2009 ,Accepted 19 March 2009.

References 

  1. Bischof F, Meyerhoff C, Pfeiffer EF. Quality control of intensified insulin therapy: HbA1 versus blood glucose. Hormone Metabolic Research. 1994, Dec;26(12):574–578
  2. Bonora E, Corrao G, Bagnardi V, Ceriello A, Comaschi M, Montanari P, et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia. 2006, May;49(5):846–854
  3. Burdick J, Chase HP, Slover RH, Knievel K, Scrimgeour L, Maniatis AK, et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics. 2004, Mar;113(3 Pt 1):e221–e224
  4. Centers for Disease Control . Toxic-shock syndrome in a patient using a continuous subcutaneous insulin infusion pump—Idaho. MMWR. 1983, Aug;1232(31):404–406
  5. DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care. 2002, Nov;25(11):2074–2080
  6. Flores L, Rodela S, Abian J, Claria J, Esmatjes E. F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: effect of glycemic control. Metabolism. 2004, Sep;53(9):1118–1120
  7. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Archives of Internal Medicine. 2003, Jun;163(11):1306–1316
  8. Hammer S, Jonker JT, Lamb HJ, van der Meer RW, Zondag W, Sepers JM, et al. Short-term hyperglycemic dysregulation in patients with type 1 diabetes does not change myocardial triglyceride content or myocardial function. Diabetes Care. 2008, May;31(8):1613–1614
  9. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Diabetes Care. 2000, Sep;23(9):1232–1235
  10. Haschke M, Zhang YL, Kahle C, Klawitter J, Korecka M, Shaw LM, et al. HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma. Clinical Chemistry. 2007, Mar;53(3):489–497
  11. Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005, Mar;28(3):533–538
  12. Hoogma RP, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Hormone and Metabolic Research. 2006, Jun;38(6):429–433
  13. Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia. 1983, May;24(5):326–329
  14. Lenhard MJ, Reeves GD. Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Archives of Internal Medicine. 2001, Oct;161(19):2293–2300
  15. Mecklenburg RS, Benson EA, Benson JW, Fredlund PN, Guinn T, Metz RJ, et al. Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. Journal of American Medical Association. 1984, Dec;252(23):3265–3269
  16. Miura J, Yamagishi S, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. Journal Diabetes Complications. 2003, Jan;17(1):16–21
  17. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Journal of American Medical Association. 2006, Apr;295(14):1681–1687
  18. Nicolls MR, Haskins K, Flores SC. Oxidant stress, immune dysregulation, and vascular function in type I diabetes. Antioxidants and Redox Signaling. 2007, Jul;9(7):879–889
  19. Pickup JC, Kidd J, Burmiston S, Yemane N. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metabolism Research and Reviews. 2006, May;22(3):232–237
  20. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care. 2002, Mar;25(3):593–598
  21. Pietri A, Raskin P. Cutaneous complications of chronic continuous subcutaneous insulin infusion therapy. Diabetes Care. 1981, Nov;4(6):624–626
  22. Reynolds LR. Reemergence of insulin pump therapy in the 1990s. Southern Medical Journal. 2000, Dec;93(12):1157–1161
  23. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radical Biology and Medicine. 2000, Feb;28(4):505–513
  24. Rosilio M, Cotton JB, Wieliczko MC, Gendrault B, Carel JC, Couvaras O, et al. Factors associated with glycemic control. A cross-sectional nationwide study in 2,579 French children with type 1 diabetes. The French Pediatric Diabetes Group. Diabetes Care. 1998, Jul;21(7):1146–1153
  25. Senstius J, Poulsen C, Hvass A. Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps. Diabetes Technology and Therapeutics. 2007, Dec;9(6):517–521
  26. Simmons BP, Hooton TM, Wong ES, Allen JR. Guidelines for prevention of intravascular infections. Infection Control. 1982;(3):61–72
  27. Tamborlane WV, Bonfig W, Boland E. Recent advances in treatment of youth with Type 1 diabetes: better care through technology. Diabetic Medicine. 2001, Nov;18(11):864–870
  28. The Diabetes Control and Complications Trial Research Group1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993, Sep;329(14):977–986
  29. van Deutekom AW, Niessen HW, Schalkwijk CG, Heine RJ, Simsek S. Increased Nepsilon-(carboxymethyl)-lysine levels in cerebral blood vessels of diabetic patients and in a (streptozotocin-treated) rat model of diabetes mellitus. European Journal of Endocrinol. 2008, May;158(5):655–660

☆ Clinical Trials Study No: NCT00461331.

☆☆ Disclosure: Ajay Rao, MD, Haytham Kawji, MD, Lillian Yau, PhD, have nothing to disclose. Dr. Vivian Fonseca has served as a consultant to Minimed, Novonordisk, and Eli Lilly.

★ This study was funded by Novonordisk through an unrestricted grant to Tulane University. This study was also supported in part by NIH Grants # 5M01RR05096 and RR-00827 in support of the General Clinical Research Center from the Division of Research Resources, National Institutes of Health (GCRC), and NIH/NIDDK P30 DK048520 (Mass Spectrometry Core). Diabetes research at Tulane University Health Sciences Center is supported in part by Susan Harling Robinson Fellowship in Diabetes Research and the Tullis-Tulane Alumni Chair in Diabetes. Dr. Fonseca is funded in part by NIH (ACCORD, TINSAL-2D), ADA, and the Tullis-Tulane Chair of Diabetes. Dr Thethi and the project described were supported by Award Number K12HD043451 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the National Institutes of Health.

PII: S1056-8727(09)00030-0

doi: 10.1016/j.jdiacomp.2009.03.002

Journal of Diabetes and Its Complications
Volume 24, Issue 2 , Pages 73-78 , March 2010

Article Tools

* Image Usage & Resolution